logo
Vertiv (VRT) Q2 Revenue Jumps 35%

Vertiv (VRT) Q2 Revenue Jumps 35%

Globe and Mail5 days ago
Key Points
Vertiv (NYSE:VRT) delivered record GAAP revenue of $2,638 million in Q2 2025, up 35.1 % year over year and beat expectations by 12.1% (GAAP).
Adjusted earnings per share rose 42% year-over-year in Q2 2025 to $0.95, outpacing analyst estimates by $0.12 (non-GAAP).
Strong orders growth and a record $8.5 billion backlog as of Q2 2025 supported a raised full-year outlook, despite temporary margin pressure from tariffs and supply chain costs.
These 10 stocks could mint the next wave of millionaires ›
Vertiv (NYSE:VRT), a global supplier of critical digital infrastructure and services for data centers and communication networks, released its second quarter results on July 30, 2025. The release detailed record GAAP revenue gains and a significant beat on non-GAAP earnings expectations. Revenue (GAAP) reached $2,638 million, compared to the analyst consensus of $2,353.9 million. Adjusted diluted earnings per share were $0.95, outpacing the $0.83 consensus. This performance was driven by surging demand for data center solutions, particularly in the Americas and Asia Pacific regions. Despite impressive sales and profit growth, higher supply chain and tariff-related costs pressured adjusted operating margins. Overall, the quarter showcased Vertiv's strong market traction and its ability to capitalize on accelerating trends in the digital infrastructure space.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (Non-GAAP) $0.95 $0.83 $0.67 41.8 %
Revenue (GAAP) $2,638 million $2,353.9 million $1,952.8 million 35.1 %
Adjusted Operating Profit $489.3 million $381.8 million 28.1 %
Adjusted Operating Margin 18.5 % 19.6 % (1.1) pp
Adjusted Free Cash Flow $277 million $336.5 million (17.7 %)
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
About Vertiv: Business Model and Strategic Focus
Vertiv provides foundational technologies for digital infrastructure. Its portfolio includes power management products, thermal management systems, racks, enclosures, and remote monitoring solutions. These products are essential for data centers, communication networks, and key industrial applications where uptime and performance are critical.
The company's recent strategic focus includes expanding its product innovation—especially in areas needed for artificial intelligence (AI) and cloud deployments—while investing in its global supply chain and manufacturing footprint. By strengthening relationships with large data center operators and technology leaders, Vertiv positions itself as a go-to partner for reliable infrastructure. Its ability to deliver on a growing backlog and execute on large-scale projects is considered central to its continued success.
Quarterly Highlights: Performance Drivers and Key Metrics
The period saw Vertiv exceed revenue and earnings expectations, reflecting exceptional demand for its digital infrastructure solutions. Organic orders expanded by roughly 15 % compared to the prior year, and the company's backlog surged to a record $8.5 billion as of Q2 2025—supported by a book-to-bill ratio of approximately 1.2x. Backlog and order strength signal continued future revenue and underline growing industry reliance on Vertiv as the market for data centers rapidly evolves.
By region, the Americas segment led growth with net sales up 42.9% (GAAP), buoyed by robust North American data center investment. Adjusted operating profit in this region increased by 34.9% compared to Q2 2024. Services & spares in the Americas were up 22.9% year-over-year for the three months ended June 30, 2025. However, additional costs from tariffs and supply chain reconfiguration led to some margin compression—adjusted operating margin in the Americas fell by 1.4 percentage points compared to Q2 2024.
The Asia Pacific segment also posted substantial gains. Net sales increased 35.1% year-over-year. Adjusted operating profit in Asia Pacific jumped 83.3%, and adjusted operating margin improved by 2.7 percentage points year over year. While service revenue growth trailed that of product sales, both areas contributed positively.
In Europe, Middle East, and Africa (EMEA), net sales grew 12.5%. Management noted that EMEA pipelines remain robust and are growing.
Innovation, Operations, and Material Events
Product innovation remains a mainstay of Vertiv's strategy, underlined by high R&D investment and recent collaboration announcements. The company continued to invest in engineering and research for its next-generation AI-optimized infrastructure. Its cooling systems, modular power solutions, and integrated white-space products are designed for demanding applications in hyperscale and AI-driven data centers. Vertiv also announced plans to acquire Great Lakes Data Racks & Cabinets, extending its portfolio in high-density racks and enclosures. This acquisition was not reflected in the current quarter's guidance and results.
Though order momentum was strong, the quarter was not without headwinds. Tariff-related expenses and the cost of rapidly shifting the company's manufacturing footprint to mitigate those tariffs weighed on margins. Management called these pressures temporary, and reiterated a plan including commercial pricing actions and supply chain reconfiguration. According to company leaders, these countermeasures should reduce the impact of tariffs toward the end of the year, but margin pressure persisted for the quarter.
On the cash flow front, adjusted free cash flow was $277 million—down 17.7% from the prior year quarter—largely due to working capital investments to support growth. Operating cash flow (GAAP) also declined versus a very strong prior year period. Still, on a year-to-date basis, adjusted free cash flow had increased 24%.
The company also did not repurchase shares, choosing instead to retain financial flexibility for future acquisitions and to maintain a conservative balance sheet.
Looking Ahead: Guidance and Key Watch Areas
Vertiv raised its financial outlook for FY2025 across most major non-GAAP metrics. For the full year 2025, the company now expects net sales between $9.93 billion and $10.08 billion, organic growth of 23 % to 25 %, adjusted operating profit (non-GAAP) of $1.95 billion to $2.03 billion, and adjusted earnings per share of $3.75 to $3.85. Guidance for adjusted free cash flow (non-GAAP) is $1.375 billion to $1.425 billion. However, management revised its margin outlook downward, with adjusted operating margin (non-GAAP) now forecast between 19.7% and 20.3%, a decrease from earlier targets.
For Q3 2025, projections include net sales of $2,510 million to $2,590 million, 20 % to 24 % organic growth, and adjusted EPS between $0.94 and $1.00. Management cautioned that these expectations do not factor in any impacts from proposed tariffs that may take effect after July 28, 2025, as regulatory clarity on additional trade policies is still pending. Vertiv's large backlog, ongoing tariff mitigation, and continued investment in manufacturing and product development will be central areas for investors to watch in the coming quarters.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 182% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 29, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CVRx (CVRX) Q2 Revenue Jumps 15%
CVRx (CVRX) Q2 Revenue Jumps 15%

Globe and Mail

time9 minutes ago

  • Globe and Mail

CVRx (CVRX) Q2 Revenue Jumps 15%

Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025

Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape
Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time2 hours ago

  • Globe and Mail

Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, 'Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Small Cell Lung Cancer Pipeline Outlook Report Key Takeaways from the Small Cell Lung Cancer Pipeline Report In August 2025, AstraZeneca announced a Phase III study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy. In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS). In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment. The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Discover how the Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies Small Cell Lung Cancer Emerging Drugs Profile AMG 757: Amgen AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer. APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC. The Small Cell Lung Cancer Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment. Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market. Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight's expert-driven report today! @ Small Cell Lung Cancer Unmet Needs Small Cell Lung Cancer Companies Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical Molecule Type Small Cell Lung Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Small Cell Lung Cancer Developments @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Small Cell Lung Cancer Pipeline Report Coverage- Global Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Small Cell Lung Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Small Cell Lung Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Small Cell Lung Cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Small Cell Lung Cancer Collaboration Deals Late Stage Products (Phase III) Pembrolizumab: Merck & Co Mid Stage Products (Phase II) Dostarlimab: GlaxoSmithKline Early Stage Products (Phase I) AMG 757: Amgen Preclinical/Discovery Stage Products S 055746: Vernalis Inactive Products Small Cell Lung Cancer Key Companies Small Cell Lung Cancer Key Products Small Cell Lung Cancer- Unmet Needs Small Cell Lung Cancer- Market Drivers and Barriers Small Cell Lung Cancer- Future Perspectives and Conclusion Small Cell Lung Cancer Analyst Views Small Cell Lung Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Ambiq Micro's IPO Could Signal the Next Wave of AI-Driven Chip Stocks
Ambiq Micro's IPO Could Signal the Next Wave of AI-Driven Chip Stocks

Globe and Mail

time2 hours ago

  • Globe and Mail

Ambiq Micro's IPO Could Signal the Next Wave of AI-Driven Chip Stocks

Key Points Ambiq Micro debuted to much fanfare on the first day of trading following its highly touted IPO. The company is a pioneer in ultra-low-power semiconductors used at the edge. While Ambiq Micro's future looks bright, that are potential risks investors shouldn't ignore. 10 stocks we like better than Ambiq Micro › Since generative artificial intelligence (AI) burst on the scene more than two years ago, some of the biggest beneficiaries have been chipmakers. More specifically, advanced semiconductors provide the computational horsepower necessary to breathe life into these AI algorithms. Nvidia, Broadcom, and Arm Holdings have all been at the forefront of AI chip design and reaped the rewards. Nvidia and Broadcom stocks have soared 961% and 439%, respectively, since late 2022, while Arm has gained 173% since its September 2023 initial public offering (IPO). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Ambiq Micro (NYSE: AMBQ) made a big splash during its public debut, as the low-power chip designer's stock surged 61% on its first day of trading last Wednesday, though it has since leveled off. Investors have been keen to profit from the ongoing adoption of AI, and the robust demand for Ambiq Micro stock suggests that power-miserly AI chip stocks could mark the next frontier. The power conundrum One of the biggest challenges associated with the increasing adoption of AI is the issue of power consumption. Most chipmakers have taken a brute-force approach, increasing the sheer magnitude of computational horsepower to decrease the time necessary to train and run these next-generation algorithms. The complex calculations required are computationally intensive, resulting in an increasing amount of energy consumption. Ambiq is taking a different approach. In the S-1 filed with the Securities and Exchange Commission (SEC) prior to its IPO, the company described itself as a "pioneer and leading provider of ultra-low-power semiconductor solutions designed to address the significant power consumption challenges of general-purpose and AI compute -- especially at the edge." Ambiq suggests its hardware and software innovations "deliver two to five times lower power consumption than traditional semiconductor design." The company is currently focused on the edge, including personal devices, as well as the medical and healthcare industries. Many of these applications are currently handled by small devices with limited battery life, where reduced power consumption is critical. In the future, Ambiq is working to expand its ultra-low-power technology to other areas of AI, including high-performance computing (HPC), data centers, and automotive, which could mark the next wave of AI chip solutions. A growing opportunity The need for power-miserly solutions could usher in the next wave of AI chips, and Ambiq's results are intriguing. For the year ended Dec. 31, the company generated revenue of $76 million, up 16% year over year, while its loss per share of $113.81 improved 24%. The trend continued in the quarter ended March 31, as revenue of $15.7 million climbed 3%, while its loss per share of $18.96 improved 30%. There is a significant concentration risk. Ambiq divulged that its top five customers accounted for 92% of revenue in the most recent quarter. Furthermore, wireless device specialist Garmin, Alphabet 's Google, and "another confidential customer" represented 38%, 25%, and 23% of net sales, respectively, according to its regulatory filing. Ambiq's flagship system-on-a-chip (SoC) is designed for smaller form-factor devices, such as smartwatches, fitness trackers, hearing aids, virtual and augmented reality glasses, and livestock tracking devices. Chief technology officer (CTO) Scott Hanson noted the company's next frontier is smart glasses. "We spent the last 10-plus years figuring out how to build the lowest power chips, and so we're in a great position to attack the same problem (on glasses)," he said. The low-power wearable chips market is expected to grow by 15% annually between 2024 and 2030 to nearly $28 billion. When viewed in the context of Ambiq's 2024 sales of $76 million, the opportunity is apparent. Every rose has its thorns It's important to remember that while Ambiq's potential is clear, risks abound. It has only just entered the glare of the public spotlight, and investors should keep in mind the aforementioned concentration risk and mounting losses, though its results are moving in the right direction. There's also the matter of Ambiq's valuation. As of market close on Monday, the stock had a market cap of roughly $673 million and trailing-12-month sales of $76.6 million. That works out to about 9 times sales, and while that's certainly not outrageous, it is a high price to pay for an unprofitable company with little public track record. As such, investors interested in taking a stake in this ultra-low-power pioneer should make Ambiq a small part of a well-balanced portfolio. Should you invest $1,000 in Ambiq Micro right now? Before you buy stock in Ambiq Micro, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ambiq Micro wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* *Stock Advisor returns as of August 4, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store